IMAX Corporation filings document the formal records behind its entertainment-technology business, NYSE-listed common shares and reported operating results. Recent Form 8-K disclosures cover quarterly and annual financial results, global box office metrics, system installations and signings, material agreements and financing activity, including convertible senior notes.
Proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Other current reports address leadership-continuity and governance disclosures, while filings also identify the company as a Canadian corporation with operations reported through Content Solutions and Technology Products and Services.
IMAX CORP Chief Executive Officer Richard Gelfond reported an option exercise and related share sale. On April 27, 2026, he converted 8,943 stock options into common shares at $31.40 per share, then sold 8,943 common shares at an average price of $37.3269 per share.
The transactions were executed pursuant to a Rule 10b5-1 plan dated December 9, 2025, and sales under that plan are now complete. Following these transactions, Gelfond holds 765,002 common shares, with remaining outstanding option, restricted share unit and common share balances of 1,332,411 stock options, 231,562 restricted share units and 765,002 common shares, respectively.
IMAX reported insider sales via a Form 144. Director Richard Gelfond reported multiple planned dispositions of Common stock by cashless exercise/same-day sale, including sales of 135,046 shares on 04/10/2026 and 121,220 shares on 03/10/2026. The filings list per-trade proceeds alongside each transaction.
IMAX Corporation is asking shareholders to vote at a virtual Annual General Meeting on June 10, 2026. Items include electing ten directors, appointing PricewaterhouseCoopers as independent auditors, and an advisory say‑on‑pay vote on executive compensation.
The company highlights a record 2025, with global box office of $1.28 billion, revenue of $410.2 million, net income of $45.5 million, and total shareholder return of over 44%. Total Adjusted EBITDA reached $184.9 million, with margins improving, and bonuses and PSUs paid above target under its pay‑for‑performance framework.
As of April 13, 2026, IMAX had 55,015,891 common shares outstanding, each carrying one vote. The Douglas Group is the largest disclosed holder, with about 15.23% of outstanding shares. The Board unanimously recommends voting FOR all three proposals.
IMAX CORP Chief Executive Officer Richard L. Gelfond exercised stock options and sold the resulting shares in pre-planned trades. On April 16–17, 2026, he converted a total of 75,919 stock options into common shares at $31.40 per share and executed open‑market sales of the same 75,919 common shares at roughly $37.05 per share, pursuant to a Rule 10b5‑1 plan dated December 9, 2025.
Following these transactions, Mr. Gelfond directly holds 765,002 common shares, with additional remaining awards of 1,341,354 outstanding stock options and 231,562 restricted share units. The options exercised were originally granted in 2016 and are scheduled to expire on June 7, 2026, so the activity reflects the use of nearing‑expiration options combined with a pre‑scheduled liquidity event.
IMAX reported that Richard Gelfond executed multiple sales of Common Stock reported on Form 144, totaling 443,159 shares. The filing lists discrete dispositions on 03/10/2026, 04/02/2026, 04/06/2026, 04/10/2026, 04/13/2026, 04/14/2026, 04/15/2026, and 04/16/2026
The listed proceeds sum to $16,979,793.05 across those transactions; the sales are shown as dispositions of shares acquired under stock options on 06/07/2016 via cashless exercise/same-day sale.
IMAX Corporation temporarily adjusted its leadership structure while CEO Richard Gelfond is on medical leave. The board appointed Robert D. Lister, currently Chief Legal Officer and Senior Executive Vice President, to serve as interim principal executive officer until May 1, 2026, when Mr. Gelfond will resume the role.
Mr. Lister will keep his existing responsibilities and will not receive any additional compensation for this interim assignment. The company states there are no special arrangements, related-party transactions, new or amended contracts, or family relationships connected to his appointment, and incorporates his biography by reference from a prior proxy statement.
Richard Gelfond reports proposed sales of Common Stock under Form 144, totaling multiple transactions in March–April 2026. The notice lists individual proposed sale quantities and gross proceeds on specific dates, including 121,220 shares for $4,860,837.15 on 03/10/2026 and 135,046 shares for $5,106,872.53 on 04/10/2026.
IMAX CORP Chief Executive Officer Richard L. Gelfond exercised stock options and sold the resulting shares in a planned series of transactions. He converted options into 120,132 common shares at $31.40 per share under a Rule 10b5-1 trading plan dated December 9, 2025.
On April 13–15, 2026, he then sold the same 120,132 common shares in open-market trades, including sales at $37.1526, $37.0678 and $37.0707 per share. Following these transactions, he directly owns 765,002 common shares, with remaining outstanding option, restricted share unit and common share balances of 1,417,273 options, 231,562 restricted share units and 765,002 common shares.
IMAX Corp. filed a Form 144 to sell 15,746 shares of Common Stock, registered for sale on 04/15/2026 on the NYSE. The filing notes the securities were acquired as compensation via stock options on 06/07/2016 and the planned sale method is "cashless exercise / same-day sale." The filing lists recent insider dispositions by Richard Gelfond totaling multiple transactions between 03/10/2026 and 04/14/2026, including sales of 121,220; 135,046; 97,462 shares on several dates with reported proceeds in the filing.